Sage TherapeuticsSAGE
SAGE
About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Employees: 487
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
155% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $1.55M
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
6.99% less ownership
Funds ownership: 91.24% [Q2] → 84.24% (-6.99%) [Q3]
9% less funds holding
Funds holding: 192 [Q2] → 175 (-17) [Q3]
37% less capital invested
Capital invested by funds: $596M [Q2] → $374M (-$222M) [Q3]
52% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 33
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
29%
downside
Avg. target
$10.18
81%
upside
High target
$26
363%
upside
11 analyst ratings
3 positive
27%
7 neutral
64%
1 negative
9%
Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target | 7%upside $6 | Hold Maintained | 16 Dec 2024 |
TD Cowen Ritu Baral 38% 1-year accuracy 3 / 8 met price target | 60%upside $9 | Hold Maintained | 21 Nov 2024 |
RBC Capital Brian Abrahams 19% 1-year accuracy 15 / 79 met price target | 29%downside $4 | Sector Perform Upgraded | 21 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target | 150%upside $14 | Neutral Reiterated | 20 Nov 2024 |
Scotiabank George Farmer 20% 1-year accuracy 4 / 20 met price target | 150%upside $14 | Sector Outperform Maintained | 30 Oct 2024 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. A.
Positive
Zacks Investment Research
1 month ago
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
Negative
Benzinga
1 month ago
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD), an inherited brain disorder that causes nerve cells in the brain to break down and die.
Negative
Market Watch
1 month ago
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease.
Negative
Reuters
1 month ago
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on Wednesday.
Neutral
Business Wire
1 month ago
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not.
Negative
Zacks Investment Research
1 month ago
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.
Neutral
Seeking Alpha
1 month ago
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Katie Plante - Manager of Investor Relations Barry E. Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - J.P.
Negative
Zacks Investment Research
1 month ago
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago.
Neutral
Business Wire
1 month ago
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are committed to harnessing the full potential of ZURZUVAE as a transformative treatment for women with postpartum depression. Our encouraging third quarter results, highlighted by continued growth in revenue and shipments, brings us one step closer to our goal of establishing ZURZUVAE as the standard of care to h.
Charts implemented using Lightweight Charts™